Document is current
Any future updates will be listed below
-
Authors
Gagnon, Eloi http://orcid.org/0000-0002-7483-1371
Pelletier, William
Gobeil, Émilie http://orcid.org/0000-0002-5365-0731
Bourgault, Jérôme http://orcid.org/0000-0002-5803-353X
Manikpurage, Hasanga D. http://orcid.org/0000-0002-2365-6956
Maltais-Payette, Ina
Abner, Erik http://orcid.org/0000-0002-6529-3161
Taba, Nele
Esko, Tõnu
Mitchell, Patricia L.
Ghodsian, Nooshin
Després, Jean-Pierre
Vohl, Marie-Claude
Tchernof, André
Thériault, Sébastien http://orcid.org/0000-0003-1893-8307
Arsenault, Benoit J.
-
Funding
Funding for this research was provided by:
EC | European Regional Development Fund (. GENTRANSMED (2014- 2020.4.01.15-0012))
- License Information
-
More Information
Article History
Received: 7 February 2022
Accepted: 29 September 2022
First Online: 13 October 2022
Competing interests
: The authors declare the following competing interests: B.J.A. is a consultant for Novartis and Silence Therapeutics and has received research contracts from Pfizer, Ionis Pharmaceuticals and Silence Therapeutics. A.T. receives research funding from Johnson & Johnson Medical Companies, Medtronic, Bodynov, and GI Windows for studies on bariatric surgery and received consulting fees from Novo Nordisk and Bausch Health. All other authors declare no competing interests.
